Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study.
Liver dysfunction is a common problem in BMT recipients and it is important to determine the etiology in order to institute appropriate therapy. The purpose of this study was to evaluate the possible causes of liver dysfunction during the first post-transplant year in BMT recipients and to identify a possible relationship between pre-existing liver dysfunction and viral hepatitis with prognosis after BMT. We reviewed liver status before and after BMT in 130 consecutive patients at the Catholic Hematopoietic Stem Cell Transplantation Center. Liver dysfunction during the first post-transplant year occurred in 85 out of 101 (84. 2%) allogeneic BMT recipients and 13 out of 29 (44.8%) autologous BMT recipients. In allogeneic BMT, GVHD and drug hepatotoxicity were major causes. In autologous BMT, drug hepatotoxicity was the most common cause. Eighteen out of 130 patients (13.8%) had abnormal liver function tests before BMT. These patients did not have an increased risk of post-transplant liver dysfunction, GVHD, and death compared to patients who had normal liver function tests prior to BMT. Nine patients were hepatitis B antigen positive and three patients were anti-HCV positive prior to BMT. There was no significant increase in the incidence of post-transplant liver dysfunction, GVHD, and death in these patients.
Department of Internal Medicine, The Catholic University of Korea, Seoul.
B K
BK
Kim
K W
KW
Chung
H S
HS
Sun
J G
JG
Suh
W S
WS
Min
C S
CS
Kang
S I
SI
Sim
W S
WS
Shin
C C
CC
Kim
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications / Q000401:mortality / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D015994:Incidence; D008107:Liver Diseases / Q000209:etiology* / Q000401:mortality / Q000821:virology; D008111:Liver Function Tests; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use / Q000633:toxicity; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014182:Transplantation, Autologous / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects
D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D011239:Prednisolone